NCT02194738
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 1377 versions: 21 with changes below, 29 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study sites revised (1660)
- Minor Study sites revised (1660)
- Minor Study sites revised (1660)
- Minor Final enrollment: 7458 participants (planned 8300)
- Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025
- Study completion pushed from Sep 28, 2026 to Sep 21, 2027
- Site details revised at 135 of 1660 sites
- Minor Study sites revised (1660)v1373
Show 16 earlier versionsHide 16 earlier versions
- Minor Study sites: 1661 to 1660v1371
- Minor Study sites revised (1661)v1370
- Minor Study sites revised (1661)v1369
- Minor Study sites revised (1661)v1368
- Minor Study sites revised (1661)v1367
- Minor Study sites revised (1661)v1366
- Minor Study sites revised (1661)v1365
- Minor Study sites revised (1661)v1364
- Minor Study sites: 1662 to 1661v1363
- Minor Study sites revised (1662)v1362
- Minor Study sites revised (1662)v1360
- Minor Study sites: 1663 to 1662v1359
- Minor Study sites revised (1663)v1358
- Minor Study sites revised (1663)v1357
- Minor Study sites revised (1663)v1348
- Study Status, Contacts/Locationsv1337
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then undergo observation.
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles in the absence of disease progression or unacceptable toxicity.
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Patients undergo observation.
Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET/CT throughout the trial and blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated.
Patients are followed serially with CT and/or PET/CT imaging for up to 1 year and then during follow-up. Patients also undergo blood sample collection during screening and follow-up. Patients may undergo an ECHO as clinically indicated on study.
Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Positron Emission Tomography
Drugs: Carboplatin, Cisplatin, Crizotinib, Erlotinib, Gemcitabine Hydrochloride, Paclitaxel, Pemetrexed, Pemetrexed Disodium
Other: Clinical Observation, Cytology Specimen Collection Procedure, Placebo Administration
Biologicals: Nivolumab, Pembrolizumab
Sites
1,660 sites in 3 countries
United States 1655, Puerto Rico 4, Guam 1